{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:10:02Z","timestamp":1787987402267,"version":"build-2784847793"},"reference-count":75,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1093\/annonc\/mdp598","type":"journal-article","created":{"date-parts":[[2010,1,30]],"date-time":"2010-01-30T03:58:58Z","timestamp":1264823938000},"page":"1395-1403","source":"Crossref","is-referenced-by-count":160,"title":["Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients"],"prefix":"10.1016","volume":"21","author":[{"given":"N.","family":"Janus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Deray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Launay-Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp598_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semnephrol.2005.06.007","article-title":"Effect of different hemodialysis regimens on genomic damage in end-stage renal failure","volume":"26","author":"Schupp","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1093\/annonc\/mdp598_bb0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)91684-0","article-title":"Increased incidence of malignancy during chronic renal failure","volume":"1","author":"Matas","year":"1975","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp598_bb0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000180813","article-title":"Increased incidence of malignancy in chronic renal failure","volume":"18","author":"Sutherland","year":"1977","journal-title":"Nephron"},{"key":"10.1093\/annonc\/mdp598_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1014489911153","article-title":"Increased incidence of neoplasia in chronic renal failure (20-year experience)","volume":"33","author":"Cengiz","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1093\/annonc\/mdp598_bb0030","first-page":"144","article-title":"Comparison and survival of patients receiving hemodialysis and peritoneal dialysis in a single center","volume":"23","author":"Uchida","year":"2007","journal-title":"Adv Perit Dial"},{"key":"10.1093\/annonc\/mdp598_bb0035","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdp598_bb0040","series-title":"Dialysis in Clinical Pharmacokinetics. Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1093\/annonc\/mdp598_bb0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2165\/00003088-199324050-00002","article-title":"Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations","volume":"24","author":"Reetze-Bonorden","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdp598_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000086591","article-title":"FHD: an index to evaluate drug elimination by hemodialysis","volume":"25","author":"Launay-Vacher","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1093\/annonc\/mdp598_bb0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0065","series-title":"GPR Anticanc\u00e9reux","author":"Launay-Vacher","year":"2009"},{"key":"10.1093\/annonc\/mdp598_bb0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357909909032859","article-title":"5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy","volume":"17","author":"Iyer","year":"1999","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdp598_bb0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000110006","article-title":"Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient","volume":"53","author":"Akiyama","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1093\/annonc\/mdp598_bb0080","first-page":"1299","article-title":"[FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure]","volume":"34","author":"Ohnishi","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/annonc\/mdp598_bb0085","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1053\/ajkd.2002.30584","article-title":"Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis","volume":"39","author":"Rengelshausen","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1093\/annonc\/mdp598_bb0090","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000189461","article-title":"Combined chemotherapy and radiotherapy for esophageal carcinoma in a hemodialyzed patient. Long-term survival","volume":"74","author":"Rebibou","year":"1996","journal-title":"Nephron"},{"key":"10.1093\/annonc\/mdp598_bb0095","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1158\/1078-0432.CCR-03-0237","article-title":"Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy","volume":"10","author":"Chung","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/00003495-200767040-00010","article-title":"Capecitabine: in advanced gastric or oesophagogastric cancer","volume":"67","author":"Dhillon","year":"2007","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdp598_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp598_bb0110","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdp598_bb0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1525-1438.2007.00847.x","article-title":"Systemic anticancer therapy in gynecological cancer patients with renal dysfunction","volume":"17","author":"Li","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000187794","article-title":"Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency","volume":"66","author":"Chatelut","year":"1994","journal-title":"Nephron"},{"key":"10.1093\/annonc\/mdp598_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","article-title":"Cisplatin (cis-diamminedichloroplatinum II)","volume":"6","author":"Prestayko","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdp598_bb0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/07357909109039874","article-title":"Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient","volume":"9","author":"Tanabe","year":"1991","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdp598_bb0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00007691-199504000-00018","article-title":"Plasma platinum elimination in a hemodialysis patient treated with cisplatin","volume":"17","author":"Gorodetsky","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdp598_bb0140","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1159\/000065582","article-title":"Full-dose chemotherapy for esophageal cancer patient under hemodialysis","volume":"92","author":"Kurisu","year":"2002","journal-title":"Nephron"},{"key":"10.1093\/annonc\/mdp598_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjc.6600687","article-title":"Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer","volume":"88","author":"Watanabe","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0150","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdp598_bb0155","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"10.1093\/annonc\/mdp598_bb0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF00548589","article-title":"Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites","volume":"19","author":"Juma","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdp598_bb0165","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000092903","article-title":"Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient","volume":"52","author":"Mencoboni","year":"2006","journal-title":"Chemotherapy"},{"key":"10.1093\/annonc\/mdp598_bb0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ndt\/gfl498","article-title":"Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer","volume":"22","author":"Hochegger","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdp598_bb0180","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF00686499","article-title":"Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis","volume":"33","author":"Yoshida","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp598_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00180192","article-title":"Pharmacokinetics of 4\u2032-epi-doxorubicin in man","volume":"1","author":"Weenen","year":"1983","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdp598_bb0195","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/030089160609200421","article-title":"Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment","volume":"92","author":"Gori","year":"2006","journal-title":"Tumori"},{"key":"10.1093\/annonc\/mdp598_bb0200","first-page":"379","article-title":"Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients","volume":"44","author":"Hande","year":"1984","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0205","first-page":"1279","article-title":"Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient","volume":"69","author":"Holthuis","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdp598_bb0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1996.14.1.257","article-title":"Predicting etoposide toxicity: relationship to organ function and protein binding","volume":"14","author":"Joel","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/annonc\/mdh008","article-title":"Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis","volume":"15","author":"Inoue","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0220","first-page":"2566","article-title":"Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function","volume":"46","author":"D'Incalci","year":"1986","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/12.1.137","article-title":"Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma","volume":"12","author":"Suzuki","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdp598_bb0230","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0235","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jjco\/hym171","article-title":"Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer","volume":"38","author":"Masumori","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0240","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00280-003-0574-3","article-title":"Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment","volume":"51","author":"Kiani","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp598_bb0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/annonc\/mdp598_bb0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.2000.tb07038.x","article-title":"Pharmacokinetics of orally administered camptothecins","volume":"922","author":"Gupta","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mdp598_bb0255","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/CAD.0b013e32811d69cb","article-title":"Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered","volume":"18","author":"Venat-Bouvet","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdp598_bb0260","first-page":"60","article-title":"Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure","volume":"25","author":"Stemmler","year":"2002","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdp598_bb0265","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cpt1973144part1572","article-title":"Pharmacokinetics of methotrexate","volume":"14","author":"Huffman","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdp598_bb0270","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0275","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.1780330724","article-title":"Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis","volume":"33","author":"Ellman","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdp598_bb0280","first-page":"1424","article-title":"Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis","volume":"26","author":"Nakamura","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1093\/annonc\/mdp598_bb0285","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/1529-0131(200005)43:5<1185::AID-ANR30>3.0.CO;2-V","article-title":"Renal failure: a risk factor for methotrexate toxicity","volume":"43","author":"Chatham","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdp598_bb0290","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/ndt\/16.5.1087","article-title":"Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis","volume":"16","author":"Boulanger","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdp598_bb0295","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ndt\/17.3.530","article-title":"Should low-dose methotrexate therapy be prescribed to dialysis patients?","volume":"17","author":"Basile","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdp598_bb0300","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ndt\/gfh357","article-title":"Neutropenia associated with the use of low-dose methotrexate in a peritoneal dialysis patient","volume":"19","author":"Chess","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdp598_bb0305","first-page":"2023","article-title":"[Effectiveness of hemodialysis in a case of acute methotrexate poisoning]","volume":"19","author":"Gauthier","year":"1990","journal-title":"Presse Med"},{"key":"10.1093\/annonc\/mdp598_bb0310","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1093\/annonc\/mdp598_bb0315","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00467-002-0946-7","article-title":"Effective removal of methotrexate by high-flux hemodialysis","volume":"17","author":"Saland","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1093\/annonc\/mdp598_bb0320","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp598_bb0325","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0330","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-07-0475","article-title":"Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function","volume":"13","author":"Takimoto","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdp598_bb0335","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jjco\/hym044","article-title":"Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysis","volume":"37","author":"Shitara","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0340","first-page":"673","article-title":"[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]","volume":"35","author":"Matoba","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/annonc\/mdp598_bb0345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s002800050868","article-title":"Pharmacokinetics of paclitaxel in an anephric patient","volume":"43","author":"Woo","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp598_bb0350","first-page":"437","article-title":"Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis\u2014case report","volume":"27","author":"Yokoyama","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1525-1438.2007.01048.x","article-title":"High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature","volume":"18","author":"Baur","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdp598_bb0360","first-page":"232","article-title":"A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis","volume":"17","author":"Balat","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0365","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/gyno.2001.6527","article-title":"Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer","volume":"84","author":"Watanabe","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0370","first-page":"2061","article-title":"[A case of non-small cell lung carcinoma successfully treated with carboplatin and weekly paclitaxel under renal dysfunction]","volume":"31","author":"Mori","year":"2004","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/annonc\/mdp598_bb0375","first-page":"21","article-title":"Pharmacokinetics and metabolism of Navelbine","volume":"16","author":"Krikorian","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdp598_bb0380","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419394888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419394888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/7\/1395\/19445945\/mdp598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T03:01:07Z","timestamp":1739761267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419394888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0923753419394888"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp598","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}